India-based global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Friday the launch of Dapagliflozin Tablets, 5 mg and 10 mg, in the United States.
Lupin's Abbreviated New Drug Application for Dapagliflozin Tablets was approved by US Food and Drug Administration (FDA) as bioequivalent to Farxiga for the indications in the approved labelling.
Farxiga, a brand of biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN), is indicated for the treatment of type 2 diabetes, chronic kidney disease, and symptomatic chronic heart failure.
Lupin's Dapagliflozin Tablets receive US regulatory approval
Dexcel Pharma's Nintedanib Capsules approved for US launch
FDA grants Fast Track status to SIM0505 for platinum‑resistant ovarian cancer
Immedica Pharma gains European approval to extend Efmody use in adrenal insufficiency
Neurocrine agrees acquisition of Soleno Therapeutics
NeuroSense's PrimeC composition receives Brazilian patent
Lilly's Foundayo (orforglipron) weight loss pill gains US FDA approval
Abbisko Therapeutics' FGFR4 inhibitor irpagratinib granted orphan designation in Europe for HCC
US FDA approves i-Lumen Scientific's i-SIGHT2 clinical study for dry AMD
Lilly to acquire Centessa Pharmaceuticals for up to USD47 per share
ALK secures EU approval for EURneffy 1 mg as needle-free adrenaline option for children
Sanofi secures EU approval for Rezurock in chronic graft-versus-host disease
Boston Scientific receives FDA clearance for Asurys fluid management system